Moreover, a number of studies have demonstrated recombinant human EPO (rhEPO), also known as erythropoiesis stimulating agents (ESAs) which have been widely used to relieve chemotherapy-induced anemia may enhance tumor progression or decrease patient survival [10–13]. The gene discussed is EPO; the disease is neoplasm.